Patient characteristics according to MN1 expression levels
Characteristic . | MN1 low . | MN1 high . | P . |
|---|---|---|---|
| Age, y | |||
| Mean | 45.3 | 46.3 | .58 |
| Range | 18-60 | 22-60 | |
| Sex, n (%) | .13 | ||
| Male | 34 (48) | 43 (61) | |
| Female | 37 (52) | 28 (39) | |
| FAB subtype, n (%) | .43 | ||
| M0 | 0 (0) | 3 (4) | |
| M1 | 5 (7) | 7 (10) | |
| M2 | 17 (24) | 21 (30) | |
| M4 | 30 (42) | 26 (37) | |
| M5 | 13 (19) | 9 (12) | |
| M6 | 3 (4) | 1 (1) | |
| M7 | 0 (0) | 0 (0) | |
| Not classified | 3 (4) | 4 (6) | |
| Type of specimen, n (%) | .16 | ||
| Bone marrow | 59 (83) | 52 (73) | |
| Peripheral blood | 12 (17) | 19 (27) | |
| % Blasts | |||
| Mean, % | 73.3 | 67.9 | .19 |
| Missing, n (%) | 3 (4) | 5 (7) | |
| Diagnosis, n (%) | .13 | ||
| De novo | 65 (92) | 59 (83) | |
| Post-MDS/secondary | 6 (8) | 12 (17) | |
| WBC count, × 109/L | |||
| Mean | 35.2 | 48.2 | .16 |
| Range | 1-226 | 1-328 | |
| ECOG performance status, n (%) | .73 | ||
| 0 | 16 (23) | 20 (28) | |
| 1 | 49 (69) | 46 (65) | |
| 2 | 6 (8) | 5 (7) | |
| FLT3-ITD, n (%) | 21 (30) | 20 (28) | .85 |
| MLL PTD, n (%) | 3 (4) | 5 (7) | .47 |
| NPM1, n (%) | |||
| Mutated | 38/48 (79) | 13/37 (35) | < .001 |
| NPM1 mutated/ FLT3ITD negative | 28/48 (58) | 8/37 (22) | .001 |
| Missing | 23 (32) | 34 (48) | |
| CD34 expression, n (%) | < .001 | ||
| CD34 low | 49 (69) | 12 (17) | |
| CD34 high | 12 (17) | 49 (69) | |
| Missing | 10 (14) | 10 (14) | |
| Induction treatment, n (%) | .047 | ||
| IVA/IVA | 63 (89) | 54 (76) | |
| IVA/FLAG-Ida | 8 (11) | 17 (24) | |
| First consolidation treatment,*n (%) | .11 | ||
| AraC/DNR | 63 (89) | 55 (77) | |
| FLAG-Ida | 6 (8) | 12 (17) | |
| Second consolidation treatment,†n (%) | .26 | ||
| HD-AraC/DNR | 27 (38) | 33 (46) | |
| Auto SCT | 23 (32) | 13 (18) | |
| Allo SCT | 18 (25) | 21 (30) |
Characteristic . | MN1 low . | MN1 high . | P . |
|---|---|---|---|
| Age, y | |||
| Mean | 45.3 | 46.3 | .58 |
| Range | 18-60 | 22-60 | |
| Sex, n (%) | .13 | ||
| Male | 34 (48) | 43 (61) | |
| Female | 37 (52) | 28 (39) | |
| FAB subtype, n (%) | .43 | ||
| M0 | 0 (0) | 3 (4) | |
| M1 | 5 (7) | 7 (10) | |
| M2 | 17 (24) | 21 (30) | |
| M4 | 30 (42) | 26 (37) | |
| M5 | 13 (19) | 9 (12) | |
| M6 | 3 (4) | 1 (1) | |
| M7 | 0 (0) | 0 (0) | |
| Not classified | 3 (4) | 4 (6) | |
| Type of specimen, n (%) | .16 | ||
| Bone marrow | 59 (83) | 52 (73) | |
| Peripheral blood | 12 (17) | 19 (27) | |
| % Blasts | |||
| Mean, % | 73.3 | 67.9 | .19 |
| Missing, n (%) | 3 (4) | 5 (7) | |
| Diagnosis, n (%) | .13 | ||
| De novo | 65 (92) | 59 (83) | |
| Post-MDS/secondary | 6 (8) | 12 (17) | |
| WBC count, × 109/L | |||
| Mean | 35.2 | 48.2 | .16 |
| Range | 1-226 | 1-328 | |
| ECOG performance status, n (%) | .73 | ||
| 0 | 16 (23) | 20 (28) | |
| 1 | 49 (69) | 46 (65) | |
| 2 | 6 (8) | 5 (7) | |
| FLT3-ITD, n (%) | 21 (30) | 20 (28) | .85 |
| MLL PTD, n (%) | 3 (4) | 5 (7) | .47 |
| NPM1, n (%) | |||
| Mutated | 38/48 (79) | 13/37 (35) | < .001 |
| NPM1 mutated/ FLT3ITD negative | 28/48 (58) | 8/37 (22) | .001 |
| Missing | 23 (32) | 34 (48) | |
| CD34 expression, n (%) | < .001 | ||
| CD34 low | 49 (69) | 12 (17) | |
| CD34 high | 12 (17) | 49 (69) | |
| Missing | 10 (14) | 10 (14) | |
| Induction treatment, n (%) | .047 | ||
| IVA/IVA | 63 (89) | 54 (76) | |
| IVA/FLAG-Ida | 8 (11) | 17 (24) | |
| First consolidation treatment,*n (%) | .11 | ||
| AraC/DNR | 63 (89) | 55 (77) | |
| FLAG-Ida | 6 (8) | 12 (17) | |
| Second consolidation treatment,†n (%) | .26 | ||
| HD-AraC/DNR | 27 (38) | 33 (46) | |
| Auto SCT | 23 (32) | 13 (18) | |
| Allo SCT | 18 (25) | 21 (30) |